Download PDF
Semin Thromb Hemost 2000; 26(5): 495-502
DOI: 10.1055/s-2000-13205
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Impaired Endogenous Fibrinolysis in Diabetes Mellitus: Mechanisms and Therapeutic Approaches

Thomas K. Nordt, Christoph Bode
  • Department of Cardiology, University of Freiburg, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

In type II diabetes mellitus the activity of the endogenous fibrinolytic system is reduced secondary to increased plasma activity of the plasminogen activator inhibitor type 1 (PAI-1). Because PAI-1 is considered an independent risk factor for cardiovascular disease, increased PAI-1 activity in diabetes mellitus may partly explain the increased susceptibility to both primary atherosclerosis and restenosis after angioplasty in this disease. The factors contributing to increased PAI-1 expression in diabetes mellitus are reviewed as well as possible therapeutic approaches to normalize increased PAI-1 expression.

KEYWORD

Plasminogen activator inhibitor - PAI-1 - hyperglycemia - hyperinsulinemia - endothelium

REFERENCES

  • 1 Andreotti F, Davies G J, Hackett D R. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardic death and stroke.  Am J Cardiol . 1988;  62 635-637
    CrossrefPubMedGoogle Scholar
  • 2 Angleton P, Chandler W L, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).  Circulation . 1989;  79 101-106
    CrossrefPubMedGoogle Scholar
  • 3 Krishnamurti C, Barr C F, Hassett M A, Young G D, Alving B M. Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits.  Blood . 1987;  69 798-803
    PubMedGoogle Scholar
  • 4 Vaughan D E, Declerck P J, van Houtte E, de Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.  Thromb Haemost . 1992;  68 60-63
    PubMedGoogle Scholar
  • 5 Levi M, Biemond B J, van Zonneveld J A, Wouter ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.  Circulation . 1992;  85 305-312
    CrossrefPubMedGoogle Scholar
  • 6 Erickson L A, Fici G J, Lund J E. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene.  Nature . 1990;  346 74-76
    CrossrefPubMedGoogle Scholar
  • 7 Carmeliet P, Stassen J M, Schoonjans L. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.  J Clin Invest . 1993;  92 2756-2760
    CrossrefPubMedGoogle Scholar
  • 8 Reilly C F, Fujita T, Hutzelmann J E, Mayer E J, Shebuski R J. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.  Circulation . 1991;  84 287-292
    PubMedGoogle Scholar
  • 9 Aznar J, Estellés A, Tormo G. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.  Br Heart J . 1988;  59 535-541
    PubMedGoogle Scholar
  • 10 Olofsson B O, Dahlén G, Nilsson T K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.  Eur Heart J . 1989;  10 77-82
    PubMedGoogle Scholar
  • 11 Huber K, Jörg M, Probst P. A decrease in plasminogen activator-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.  Thromb Haemost . 1992;  67 209-213
    PubMedGoogle Scholar
  • 12 Verheugt F WA, ten Cate W J, Sturk A. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.  Am J Cardiol . 1987;  59 1075-1079
    CrossrefPubMedGoogle Scholar
  • 13 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.  N Engl J Med . 1985;  313 1557-1563
    CrossrefPubMedGoogle Scholar
  • 14 Hamsten A, de Faire U, Waldius G. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction.  Lancet . 1987;  2 3-8
    PubMedGoogle Scholar
  • 15 Salomaa V, Stinson V, Kark J D. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study.  Circulation . 1995;  91 284-290
    PubMedGoogle Scholar
  • 16 Cortellaro M, Cofrancesco E, Boschetti C. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study.  Arterioscler Thromb . 1993;  13 1412-1417
    PubMedGoogle Scholar
  • 17 Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease.  Semin Thromb Hemost . 1990;  16 207-216
    PubMedGoogle Scholar
  • 18 Grimaudo V, Bachmann F, Hauert J, Christe M A, Kruithof E KO. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.  Thromb Haemost . 1992;  67 397-401
    PubMedGoogle Scholar
  • 19 Barbash G I, Hod H, Roth A. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.  Am J Cardiol . 1989;  64 1231-1235
    CrossrefPubMedGoogle Scholar
  • 20 Sane D C, Stump D C, Topol E J. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.  Thromb Haemost . 1991;  65 275-279
    PubMedGoogle Scholar
  • 21 Nordt T K, Moser M, Kohler B. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.  Thromb Haemost . 1998;  80 881-886
    PubMedGoogle Scholar
  • 22 Schleef R R, Higgins D L, Pillemer E, Levitt L J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.  J Clin Invest . 1989;  83 1747-1752
    CrossrefPubMedGoogle Scholar
  • 23 Diéval J, Nguyen G, Gross S, Delobel J, Kruithof E KO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.  Blood . 1991;  77 528-532
    PubMedGoogle Scholar
  • 24 Fay W P, Shapiro A D, Shih J L, Schleef R R, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation.  N Engl J Med . 1992;  327 1729-1733
    PubMedGoogle Scholar
  • 25 Lee M H, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.  Blood . 1993;  81 2357-2362
    PubMedGoogle Scholar
  • 26 Nordt T K, Peter K, Ruef J, Kübler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.  Thromb Haemost . 1999;  82(Suppl) 14-18
    PubMedGoogle Scholar
  • 27 Factor S M, Segal B H, van Hoeven H K. Diabetes and coronary artery disease.  Coronary Artery Dis . 1992;  3 4-10
    PubMedGoogle Scholar
  • 28 Califf R M, Fortin D F, Frid D J. Restenosis after coronary angioplasty: An overview.  J Am Coll Cardiol . 1991;  17 2B-13B
    PubMedGoogle Scholar
  • 29 Sobel B E. Potentiation of vasculopathy by insulin: Implications from an NHLBI Clinical Alert.  Circulation . 1996;  93 1613-1615
    PubMedGoogle Scholar
  • 30 The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.  N Engl J Med . 1996;  335 217-225
    CrossrefPubMedGoogle Scholar
  • 31 Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.  Diabetologia . 1991;  34 457-462
    CrossrefPubMedGoogle Scholar
  • 32 Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherosclerosis in type II diabetic patients.  Diabetes . 1993;  42 1-7
    PubMedGoogle Scholar
  • 33 Falk E, Shah P K, Fuster V. Coronary plaque disruption.  Circulation . 1995;  92 657-671
    CrossrefPubMedGoogle Scholar
  • 34 Bakker C M, Metselaar H J, Groenland T N. Increased tissue-type plasminogen activator activity in orthotopic but not heterotopic liver transplantation: The role of the anhepatic period.  Hepatology . 1992;  16 404-408
    PubMedGoogle Scholar
  • 35 Kooistra T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis.  Fibrinolysis . 1990;  4(Suppl 2) 33-39
    PubMedGoogle Scholar
  • 36 Maiello M, Boeri D, Podesta F. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.  Diabetes . 1992;  41 1009-1015
    PubMedGoogle Scholar
  • 37 Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expression of genes related to the extracellular matrix in human endothelial cells.  J Biol Chem . 1991;  266 14244-14250
    PubMedGoogle Scholar
  • 38 Nordt T K, Klassen K J, Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.  Arterioscler Thromb . 1993;  13 1822-1828
    PubMedGoogle Scholar
  • 39 Hughes H H. Swine in cardiovascular research.  Lab Anim Sci . 1986;  36 348-350
    PubMedGoogle Scholar
  • 40 van Hinsbergh W M V, Binnema D, Scheffer M A. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels.  Arteriosclerosis . 1987;  7 389-400
    PubMedGoogle Scholar
  • 41 Nordt T K, Schneider D J, Sobel B E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: A potential risk factor for vascular disease.  Circulation . 1994;  89 321-330
    PubMedGoogle Scholar
  • 42 Sobey W J, Beer S F, Carrington C A. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.  Biochem J . 1989;  260 535-541
    PubMedGoogle Scholar
  • 43 Bowsher R R, Wolny J D, Frank B H. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum.  Diabetes . 1992;  41 1084-1090
    PubMedGoogle Scholar
  • 44 Temple R C, Clark P MS, Nagi D K. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics.  Clin Endocrinol . 1990;  32 689-693
    PubMedGoogle Scholar
  • 45 Nagi D K, Hendra T J, Ryle A J. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia . 1990;  33 532-537
    CrossrefPubMedGoogle Scholar
  • 46 Heding L G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients.  Diabetologia . 1972;  8 260-266
    CrossrefPubMedGoogle Scholar
  • 47 Alessi M C, Juhan-Vague I, Kooistra T, Declerck P J, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.  Thromb Haemost . 1988;  60 491-494
    PubMedGoogle Scholar
  • 48 Kooistra T, Bosma P J, Töns H AM. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes.  Thromb Haemost . 1989;  62 123-128
    PubMedGoogle Scholar
  • 49 Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states.  Proc Natl Acad Sci USA . 1991;  88 9959-9963
    PubMedGoogle Scholar
  • 50 Spradlin C T, Galloway J A, Anderson J H. Apparent increase in coronary heart disease with human proinsulin (HPI): Randomization failure or HPI effect?.  Diabetologia . 1990;  33(Suppl) A60
    CrossrefPubMedGoogle Scholar
  • 51 Galloway J A, Hooper S A, Spradlin C T. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.  Diabetes Care . 1992;  15 666-692
    CrossrefPubMedGoogle Scholar
  • 52 Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) avtivity and proinsulin-like molecules independently of glycemic control.  Diabetic Med . 1993;  10 27-32
    CrossrefPubMedGoogle Scholar
  • 53 Misbin R I, Merimee T J, Lowenstein J M. Insulin removal by isolated perfused rat liver.  Am J Physiol . 1976;  230 171-177
    PubMedGoogle Scholar
  • 54 Glauber H S, Henry R R, Wallace P. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.  N Engl J Med . 1987;  316 443-449
    PubMedGoogle Scholar
  • 55 Nordt T K, Sawa H, Fujii S, Sobel B E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.  Circulation . 1995;  91 764-770
    CrossrefPubMedGoogle Scholar
  • 56 Fujii S, Sobel B E. Induction of plasminogen activator inhibitor by products released from platelets.  Circulation . 1990;  82 1485-1493
    PubMedGoogle Scholar
  • 57 Nordt T K, Sawa H, Fujii S, Sobel B E. Hyperinsulinemia increases plasma activity of PAI-1 in vivo independently of an acute phase reaction.  Fibrinolysis . 1997;  11(Suppl 1) 51-54
    PubMedGoogle Scholar
  • 58 Nordt T K, Sawa H, Fujii S, Bode C, Sobel B E. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo.  J Mol Cell Cardiol . 1998;  30 1535-1543
    CrossrefPubMedGoogle Scholar
  • 59 Grant P J, Kruithof E KO, Felley C P, Felber J P, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 conmcentratiosn in man.  Clin Sci . 1990;  79 513-516
    CrossrefPubMedGoogle Scholar
  • 60 Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man.  Thromb Haemost . 1991;  65 130-133
    PubMedGoogle Scholar
  • 61 Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man.  Thromb Haemost . 1992;  67 117-120
    PubMedGoogle Scholar
  • 62 Potter van Loon J B, de Bart C W A, Radder J K. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans.  Fibrinolysis . 1990;  4(Suppl 2) 93-94
    PubMedGoogle Scholar
  • 63 Frick M H, Elo O, Haapa K. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.  N Engl J Med . 1987;  317 1237-1245.
    CrossrefPubMedGoogle Scholar
  • 64 Manninen V, Elo M O, Frick M H. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.  JAMA . 1988;  260 641-651
    CrossrefPubMedGoogle Scholar
  • 65 Tenkanen L, Mänttäri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.  Circulation . 1995;  92 1779-1785
    PubMedGoogle Scholar
  • 66 Huttunen J K, Heinonen O P, Manninen V. The Helsinki Heart Study: An 8.5-year safety and mortality follow-up.  J Intern Med . 1994;  235 31-39
    PubMedGoogle Scholar
  • 67 Avellone G, Di Garbo V, Panno A V. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia.  Int Angiol . 1988;  7 270-277
    PubMedGoogle Scholar
  • 68 Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.  Thromb Haemost . 1990;  63 174-177
    PubMedGoogle Scholar
  • 69 Nordt T K, Kornas K, Peter K. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type-1 induced by insulin and its precursors.  Circulation . 1997;  95 677-683
    PubMedGoogle Scholar
  • 70 Nilsson L, Takemura T, Eriksson P, Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.  Arterioscler Thromb Vasc Biol . 1999;  19 1577-1581
    PubMedGoogle Scholar
  • 71 Keber I, Lavre J, Suc S, Keber D. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates.  Fibrinolysis . 1994;  8(Suppl 2) 57-59
    PubMedGoogle Scholar
  • 72 Bröijersen A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia.  No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol . 1996;  16 511-516
    PubMedGoogle Scholar
  • 73 Cimminiello C, Vigorelli P, Piliego T. Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol.  Biomed Pharmacother . 1997;  51 164-169
    CrossrefPubMedGoogle Scholar
  • 74 Kockx M, de Maat P M M, Knipscheer H C. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidemic patients.  Thromb Haemost . 1997;  78 1167-1172
    PubMedGoogle Scholar
  • 75 Jeng J R, Jeng C Y, Sheu W H. Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance.  Am Heart J . 1997;  134 565-571
    PubMedGoogle Scholar
  • 76 Pazzucconi F, Mannucci L, Mussoni L. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridemia.  Eur J Clin Pharmacol . 1992;  43 219-223
    PubMedGoogle Scholar